Literature DB >> 25128502

In silico prediction of major drug clearance pathways by support vector machines with feature-selected descriptors.

Kouta Toshimoto1, Naomi Wakayama1, Makiko Kusama1, Kazuya Maeda1, Yuichi Sugiyama1, Yutaka Akiyama2.   

Abstract

We have previously established an in silico classification method ("CPathPred") to predict the major clearance pathways of drugs based on an empirical decision with only four physicochemical descriptors-charge, molecular weight, octanol-water distribution coefficient, and protein unbound fraction in plasma-using a rectangular method. In this study, we attempted to improve the prediction performance of the method by introducing a support vector machine (SVM) and increasing the number of descriptors. The data set consisted of 141 approved drugs whose major clearance pathways were classified into metabolism by CYP3A4, CYP2C9, or CYP2D6; organic anion transporting polypeptide-mediated hepatic uptake; or renal excretion. With the same four default descriptors as used in CPathPred, the SVM-based predictor (named "default descriptor SVM") resulted in higher prediction performance compared with a rectangular-based predictor judged by 10-fold cross-validation. Two SVM-based predictors were also established by adding some descriptors as follows: 1) 881 descriptors predicted in silico from the chemical structures of drugs in addition to 4 default descriptors ("885 descriptor SVM"); and 2) selected descriptors extracted by a feature selection based on a greedy algorithm with default descriptors ("feature selection SVM"). The prediction accuracies of the rectangular-based predictor, default descriptor SVM, 885 descriptor SVM, and feature selection SVM were 0.49, 0.60, 0.72, and 0.91, respectively, and the overall precision values for these four methods were 0.72, 0.77, 0.86, and 0.98, respectively. In conclusion, we successfully constructed SVM-based predictors with limited numbers of descriptors to classify the major clearance pathways of drugs in humans with high prediction performance.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Year:  2014        PMID: 25128502     DOI: 10.1124/dmd.114.057893

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  In Silico Prediction of Major Clearance Pathways of Drugs among 9 Routes with Two-Step Support Vector Machines.

Authors:  Naomi Wakayama; Kota Toshimoto; Kazuya Maeda; Shun Hotta; Takashi Ishida; Yutaka Akiyama; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2018-08-24       Impact factor: 4.200

Review 2.  BDDCS, the Rule of 5 and drugability.

Authors:  Leslie Z Benet; Chelsea M Hosey; Oleg Ursu; Tudor I Oprea
Journal:  Adv Drug Deliv Rev       Date:  2016-05-13       Impact factor: 15.470

Review 3.  Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes.

Authors:  Hannu Raunio; Mira Kuusisto; Risto O Juvonen; Olli T Pentikäinen
Journal:  Front Pharmacol       Date:  2015-06-12       Impact factor: 5.810

4.  Computational Construction of Antibody-Drug Conjugates Using Surface Lysines as the Antibody Conjugation Site and a Non-cleavable Linker.

Authors:  Arianna Filntisi; Dimitrios Vlachakis; George K Matsopoulos; Sophia Kossida
Journal:  Cancer Inform       Date:  2014-12-08

5.  Development of an in silico prediction system of human renal excretion and clearance from chemical structure information incorporating fraction unbound in plasma as a descriptor.

Authors:  Reiko Watanabe; Rikiya Ohashi; Tsuyoshi Esaki; Hitoshi Kawashima; Yayoi Natsume-Kitatani; Chioko Nagao; Kenji Mizuguchi
Journal:  Sci Rep       Date:  2019-12-11       Impact factor: 4.379

6.  Artificial Intelligence (AI) to the Rescue: Deploying Machine Learning to Bridge the Biorelevance Gap in Antioxidant Assays.

Authors:  Sunday Olakunle Idowu; Amos Akintayo Fatokun
Journal:  SLAS Technol       Date:  2020-10-15       Impact factor: 3.047

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.